Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
tag
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
JNJ

Prezzo Johnson & Johnson

Closed
JNJ
$221,32
-$1,19(-0,53%)

*Data last updated: 2026-05-10 11:08 (UTC+8)

As of 2026-05-10 11:08, Johnson & Johnson (JNJ) is priced at $221,32, with a total market cap of $532,76B, a P/E ratio of 18,80, and a dividend yield of 2,34%. Today, the stock price fluctuated between $220,93 and $223,33. The current price is 0,17% above the day's low and 0,90% below the day's high, with a trading volume of 3,85M. Over the past 52 weeks, JNJ has traded between $149,04 to $251,71, and the current price is -12,07% away from the 52-week high.

JNJ Key Stats

Yesterday's Close$222,51
Market Cap$532,76B
Volume3,85M
P/E Ratio18,80
Dividend Yield (TTM)2,34%
Dividend Amount$1,34
Diluted EPS (TTM)8,60
Net Income (FY)$26,80B
Revenue (FY)$94,19B
Earnings Date2026-07-15
EPS Estimate2,83
Revenue Estimate$24,95B
Shares Outstanding2,39B
Beta (1Y)0.263
Ex-Dividend Date2026-05-26
Dividend Payment Date2026-06-09

About JNJ

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
SectorHealthcare
IndustryDrug Manufacturers - General
CEOJoaquin Duato
HeadquartersNew Brunswick,NJ,US
Official Websitehttps://www.jnj.com
Employees (FY)138,20K
Average Revenue (1Y)$681,57K
Net Income per Employee$193,95K

Johnson & Johnson (JNJ) FAQ

What's the stock price of Johnson & Johnson (JNJ) today?

x
Johnson & Johnson (JNJ) is currently trading at $221,32, with a 24h change of -0,53%. The 52-week trading range is $149,04–$251,71.

What are the 52-week high and low prices for Johnson & Johnson (JNJ)?

x

What is the price-to-earnings (P/E) ratio of Johnson & Johnson (JNJ)? What does it indicate?

x

What is the market cap of Johnson & Johnson (JNJ)?

x

What is the most recent quarterly earnings per share (EPS) for Johnson & Johnson (JNJ)?

x

Should you buy or sell Johnson & Johnson (JNJ) now?

x

What factors can affect the stock price of Johnson & Johnson (JNJ)?

x

How to buy Johnson & Johnson (JNJ) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Hot Posts su Johnson & Johnson (JNJ)

NodeGuardian

NodeGuardian

10 ore fa
Johnson & Johnson (NYSE: JNJ) will participate in the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th. Management will hold a Fireside Chat at 11:30 a.m. Eastern Time, which will be accessible via a live audio webcast on the company's investor website. An audio webcast replay will be available approximately 48 hours after the event.
0
0
0
0
MrDecoder

MrDecoder

10 ore fa
Breakfast News: Novo Seeks Edge With OpenAI Deal ------------------------------------------------ ### April 14, 2026 | Monday's Markets | | --- | | **S&P 500** 6,886 (+1.02%) | | **Nasdaq** 23,184 (+1.23%) | | **Dow** 48,218 (+0.63%) | | **Bitcoin** $73,075 (+2.82%) | Source: Image created by Jester AI. 1. Novo Nordisk Taps OpenAI for Drug R&D ---------------------------------------- **Novo Nordisk** (NVO +0.57%) announced a new partnership with OpenAI, designed to push AI transformation in healthcare and help bring new and enhanced treatments to patients quicker. The stock rose over 2.5% before the market opened. * **"We know there are therapies still waiting to be discovered that could change their lives":** Mike Doustdar, Novo's CEO, explained how OpenAI's advanced capabilities should give "us the ability to analyze datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever." * **"The thing with Novo is they look pretty cheap right now":** Last month, Fool analyst Karl Thiel said "I think investors see slowing growth and more looming competition" but "they just need the right deal or the right internal development to change that calculus." 2. Bloom Energy Pops on Broader Oracle Deal ------------------------------------------- **Bloom Energy** (BE +0.92%) rose over 15% ahead of the market open after confirming the expansion of an existing partnership with **Oracle** (ORCL +0.75%), more than doubling the amount of gigawatt power supply. * **"The expanded partnership underscores Bloom's capability to provide fast, reliable power suited for AI workloads":** Bloom's statement confirmed Oracle now intends to procure up to 2.8 gigawatts of Bloom's fuel cell systems in the coming years, primarily to support Oracle's projects in the U.S. * **The news reflects a growing shift away from traditional power systems:** Bloom's modular fuel cell systems can be deployed far faster than traditional power solutions, making it more appealing for large tech companies like Oracle in the race to get operational. 3. United CEO Allegedly Floats Huge Merger ------------------------------------------ **United Airlines** (UAL 0.12%) CEO Scott Kirby has reportedly pitched the potential of merging with **American Airlines** (AAL +1.29%) to President Trump, in a move that would create the largest airline on the planet. * **Details emerging from White House meeting from late February:** Sources didn't confirm if any process was underway in the background, but Kirby has mentioned in the past that a combined airline would aid the company in international markets. * **Any deal would likely face significant regulatory hurdles:** United and American were already the world's two largest airlines by available capacity in 2025. Any tie-up could struggle to get approval given the potential opposition from unions, rivals and lawmakers. 4. Key Pre-Market Earnings on Tuesday ------------------------------------- * **CarMax **(KMX +1.08%) tumbled over 8% in pre-market trading due to a 1.8% fall in used and wholesale vehicle sales, as recorded in the latest quarterly report. It compounds the 47% drop in earnings last quarter, as the company continues to grapple with weak demand. * **JPMorgan Chase** (JPM 1.34%) fell over 3% before the market opened after quarterly results showed expenses rose by 14% off the back of higher investments in tech and marketing. CEO Jamie Dimon spoke of "an increasingly complex set of risks – such as geopolitical tensions and wars." * **Johnson & Johnson **(JNJ 0.54%) was little changed ahead of the opening bell after raising its full-year 2026 guidance, with quarterly reported sales up 9.9%, building on momentum from the product launches from last quarter. 5. Your Take ------------ **What's your take on investing in banks? Do you own any bank stocks – and if so, which ones and why?** Debate with friends and family, or become a member to hear what your fellow Fools are saying!
BTC+0,68%
0
0
0
0
ForkLibertarian

ForkLibertarian

12 ore fa
**Key Takeaways ** * The US stock market is trading at 5% discount to a composite of our valuations. * Valuation dislocation across styles narrowed, with growth and value both at 7% discounts. * April’s market leadership was highly concentrated, driven mainly by artificial intelligence and mega-cap winners. * AI remains the dominant earnings and investment theme. As of April 30, 2026, the US equity market was trading at a 5% discount to a composite of our fair value estimates of the over 700 stocks we cover that trade on US exchanges. Our price/fair value metric fell to as low as 0.88 at the end of March, before the April market rally brought it back up to 0.95. Price/Fair Value of Morningstar's U.S. Equity Research Coverage at Month End ----------------------------------------------------------------------------------- ![](https://img-cdn.gateio.im/social/moments-992a63306d-0ff426a500-8b7abd-e5a980) Source: Morningstar Research Services, LLC. Data as of April 30, 2026. Barbell Portfolio Reallocation Update ------------------------------------- In our 2026 Market Outlook, we warned that several key emerging risks could lead to this year being more volatile than last. In order to take advantage of this volatility, we recommended a barbell-shaped portfolio. One half of the barbell is invested in high-quality, value stocks (especially undervalued energy stocks), with the other half of the barbell being invested in growth stocks (especially undervalued technology and AI). On the March 30 episode of _The Morning Filter_ podcast, we recommended that it was time to start harvesting profits in the value category, specifically energy stocks, and reallocate those proceeds into the growth category, specifically into technology and AI stocks. At that point, the Morningstar US Value Index had risen 1% year to date, and the Morningstar US Energy Index had risen 41%. Comparatively, the Morningstar US Growth Index had dropped over 9%, and the Morningstar US Technology Index had fallen over 11%. Since we made that reallocation recommendation, growth stocks have staged a strong comeback, rising 12% in April, and technology stocks surged over 17%. Value stocks lagged in April, only rising 3%, and energy stocks retreated 5%. Following these returns and incorporating our fair value changes over the course of April, valuations have become much less skewed. Both growth and value stocks are trading at a 7% discount to our valuations, whereas core stocks remain much closer to fair value. By capitalization, small-cap stocks remain the most undervalued at an 18% discount, while both large- and mid-cap stocks are at a 4% discount. Change in Price/Fair Value by Morningstar Style Box ---------------------------------------------------------- ![](https://img-cdn.gateio.im/social/moments-03c4fbbfa8-3302f65f81-8b7abd-e5a980) Source: Morningstar Research Services, LLC. Data as of April 30, 2026. Return Dispersion Across Sectors -------------------------------- As we detailed in our March 2026 outlook, the relatively narrow trading range at the broad index level has masked significant sector‑level rotation occurring beneath the surface. The communications sector led the market higher in April, surging over 18%. Almost the entire gain was driven by 4-star-rated Alphabet GOOGL. The technology sector was close behind, surging over 17% in April. Gains across the technology sector were much more broadly spread across the sector, yet the greatest individual contributors included AI-driven stocks such as Nvidia NVDA, Broadcom AVGO, and Advanced Micro Devices AMD. The consumer cyclical sector also posted a double-digit gain in April, yet almost the entire return was driven by Amazon.com AMZN, which started the month as a 4-star-rated stock. Excluding Amazon, much of the sector remained moribund. Only two sectors registered losses in April. Energy fell approximately 3% as oil prices subsided and healthcare posted a slight loss. While 2-star-rated Johnson & Johnson JNJ was the single greatest detractor to returns, losses were widespread across the sector. Morningstar Sector Index Returns – April 2026 (%) -------------------------------------------------------- ![](https://img-cdn.gateio.im/social/moments-4ff00fcf35-2ac2278fd1-8b7abd-e5a980) Source: Morningstar Research Services, LLC. Data as of April 30, 2026. Looking Forward, Technology Remains Most Undervalued ---------------------------------------------------- Even after the strong returns in April, the technology sector remains the most undervalued, trading at an 11% discount to fair value. While the technology sector contains some of the most undervalued mega-cap stocks tied to artificial intelligence, such as Nvidia and Broadcom, it also contains some of the stocks we think are most overvalued in today’s market, such as Ciena CIEN and Western Digital WDC. The healthcare sector is the second most undervalued at a 7% discount. The area that we see the most opportunity is in medical devices, diagnostics, and instruments such as Danaher DHR, Medtronic MDT, and Abbott ABT. At a 5% discount, financial services and real estate tied for the third most undervalued sector. The financial-services sector was the second most overvalued coming into the year and is the second worst performing sector year to date. Real estate started the year as the most undervalued sector and has performed admirably, rising over 10% year to date. By market capitalization, the most attractive segment in real estate is the cellphone tower REITs, such as American Tower AMT and Crown Castle CCI, which remain out of favor. On the flip side of the coin, the consumer defensive sector is the most overvalued at a 19% premium. Yet, this premium is heavily skewed by 1-star-rated mega-cap stocks Walmart WMT and Costco COST. Excluding these from our valuation, the sector valuation is much closer to being fairly valued. After rallying over 14% year to date, the basic materials sector is the next most overvalued at a 12% premium. Similarly, after rallying almost 17% this year on the strength of supplying the AI-buildout boom, the industrials sector is 8% overvalued. Morningstar Price/Fair Value by Sector --------------------------------------------- ![](https://img-cdn.gateio.im/social/moments-8de3db72ee-c67c8bad22-8b7abd-e5a980) Source: Morningstar Research Services, LLC. Data as of April 30, 2026. Earnings Season Takeaway: It’s Still All About AI ------------------------------------------------- The AI-buildout boom remains full speed ahead. This earnings season, expectations for companies most closely tied to the AI-buildout boom were high, and these companies did not disappoint. Generally, everyone beat expectations both on the top line as well as the bottom line, and in many cases by a lot. Almost all these companies boosted their guidance to some degree, and many increased their guidance for the amount they plan to spend on capital expenditures. The race to build out ever-increasing generative capacity is the modern-day version of the gold rush. Each of these companies is in a race to build out capacity faster than competitors; each wants to capture a first-mover advantage, as their biggest concern is that laggards will end up in the scrap heap of history. Looking forward, investors need to be judicious in their decisions about which AI stocks to invest in. On the one hand, we see a number of undervalued opportunities among those companies that are the leaders in their respective AI buildout and use cases. Stocks such as wide-moat-rated Nvidia, Alphabet, and Broadcom trade at enough margin of safety to be rated 4-stars. Yet, we also see areas that we think are overextended. For example, some of the most overvalued stocks we cover are technology companies whose hardware products are commodity-oriented and do not have an economic moat. The huge demand from the AI-buildout boom has led to an undersupply of these products in the short term, but once the excess demand abates and new supply comes online, we expect the high prices they can charge to plummet back to Earth, and the record operating margins they earn today will quickly contract.
0
0
0
0